Cantor Fitzgerald Lowers AbbVie (NYSE:ABBV) Price Target to $240.00

AbbVie (NYSE:ABBV) had its price objective lowered by research analysts at Cantor Fitzgerald from $250.00 to $240.00 in a research note issued on Wednesday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Cantor Fitzgerald’s price target would suggest a potential upside of 16.39% from the company’s current price.

Several other equities analysts also recently weighed in on the company. Weiss Ratings reiterated a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, January 21st. BMO Capital Markets reaffirmed an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Evercore decreased their target price on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 4th. Sanford C. Bernstein restated a “market perform” rating on shares of AbbVie in a report on Thursday, February 5th. Finally, Citigroup dropped their price target on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a research report on Tuesday, January 27th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $252.65.

AbbVie Trading Down 0.2%

ABBV stock opened at $206.21 on Wednesday. AbbVie has a 12 month low of $164.39 and a 12 month high of $244.81. The firm has a 50-day moving average of $220.95 and a two-hundred day moving average of $224.28. The company has a market cap of $364.61 billion, a price-to-earnings ratio of 87.38, a PEG ratio of 0.73 and a beta of 0.38.

AbbVie (NYSE:ABBV) last announced its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.65 by $0.06. The business had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The business’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, equities analysts forecast that AbbVie will post 12.31 earnings per share for the current year.

Insiders Place Their Bets

In other news, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the sale, the senior vice president directly owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. The trade was a 66.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of the firm’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the sale, the executive vice president owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 0.25% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Evolution Wealth Management Inc. bought a new position in shares of AbbVie in the 2nd quarter worth about $26,000. Chelsea Counsel Co. bought a new position in AbbVie during the 3rd quarter worth $26,000. Litman Gregory Wealth Management LLC acquired a new stake in AbbVie in the fourth quarter worth $28,000. Westend Capital Management LLC bought a new position in shares of AbbVie during the fourth quarter worth about $29,000. Finally, Imprint Wealth LLC raised its holdings in shares of AbbVie by 56.3% during the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after buying an additional 45 shares during the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: New dermatology data presented at the American Academy of Dermatology strengthen long‑term efficacy/safety and quality‑of‑life profiles for Skyrizi (risankizumab) and Rinvoq (upadacitinib); FDA label expansion for Skyrizi (genital and scalp psoriasis) supports continued market momentum for AbbVie’s high‑growth immunology portfolio. Can AbbVie’s New Dermatology Data Quietly Reshape Its Immunology-Heavy Investment Story?
• Positive Sentiment: J.P. Morgan issued a constructive call with a $260 price target, framing recent weakness as a buying opportunity and providing a potential catalyst if sentiment improves. AbbVie Gets JPMorgan Buying Opportunity Call With $260 Price Target
• Positive Sentiment: Allergan Aesthetics initiatives (Botox® Cosmetic grants program and a new Allergan Medical Institute center) bolster the aesthetics franchise’s brand/education footprint and may support non‑immunology revenue. BOTOX® Cosmetic Empowers Women Entrepreneurs Allergan Aesthetics Third State-of-the-Art AMI Center Opens
• Neutral Sentiment: AbbVie updated investors on a real‑world Parkinson’s observational study in Belgium — progress to monitor but not an immediate revenue driver. AbbVie’s Real‑World Parkinson’s Study in Belgium
• Neutral Sentiment: AbbVie faces an earnings event (Q1) at the end of April — analysts and investors are positioning ahead of guidance and cadence comments. Should You Buy AbbVie Stock Before April 29?
• Negative Sentiment: AbbVie placed Humira on the White House’s TrumpRx platform at a steep (~86%) discount — a pricing concession that could weigh on Humira revenue and raises fresh questions about valuation and pricing strategy for legacy products. AbbVie Puts Humira on TrumpRx at Steep Discount Humira’s TrumpRx Discount Raises New Questions For AbbVie Valuation
• Negative Sentiment: Shares have underperformed peers and recently slipped despite broader market gains, reflecting investor concern over Humira pricing, competition and the high earnings bar for 2026. AbbVie Stock Drops Despite Market Gains

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.